ABCL
AbCellera Biologics Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 27 ▲ 2 insiders buy $276.4K at $3.43
- Feb 27 ▲ Two insiders at AbCellera Biologics purchased shares in the open mar…
- May 11 ▲ AbCellera reported Q1 2026 revenue of $8.3M (up 96% YoY from $4.2M)…
- May 14 ▲ 1 insider buy $95.4K at $4.77
- Jul 29 ▲ AbCellera announced a collaboration with Vertex Pharmaceuticals to d…
- Aug 10 ▲ AbCellera announced positive top-line Phase 2 results for ABCL635, a…
- Aug 11 ▼ AbCellera Biologics Inc. filed a preliminary prospectus supplement f…
- Aug 12 to Aug 24 ▲ 4 days of insider buys: $1.5M by 3 insiders, avg $10.50
- Aug 15 ▼ AbCellera Biologics (ABCL) saw a mixed institutional cluster in Q2 2…
- Oct 12 UBS initiates
- Nov 9 Trial readout: T-90d Trial Readout: ABCL635 (Phase 2)
- Nov 12 to Nov 13 ▲ 2 days of insider buys: $796.4K by 2 insiders, avg $11.51
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersBULLISH
4 insiders bought $2.7M at an average $8.56. No open-market sales. Price is 30% above their cost.
- InstitutionsMIXED
Q2 2026: 15 added (1 new), 19 trimmed or exited. Largest new: Price T Rowe Associates /Md/ $12.5M.
- AnalystsBULLISH
16 of 18 rate it Buy or better.
- Short sellersSTEADY
Short interest −6.2% to 29.02M shares. 8.5 days to cover, ≈9.0% of shares.
- TrendDOWNTREND
10% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 30.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | $48.2M |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | TRIM | $33.9M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | TRIM | $22.5M |
| MARSHALL WACE, LLP | DOUBLED | $14.9M |
| UBS Group AG | TRIM | $14.7M |
| PRICE T ROWE ASSOCIATES INC /MD/ | NEW | $12.5M |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | $9.7M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $7.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 16, 2026 | 🔒 Fresh data, subscribers only MAINTAIN | |
| Nov 11, 2026 | StoneX MAINTAIN | Buy |
| Nov 10, 2026 | Stifel MAINTAIN | Buy |
| Oct 12, 2026 | UBS INITIATE | Buy |
| Sep 29, 2026 | JP Morgan INITIATE | Overweight |
| Aug 11, 2026 | Truist Securities MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 13, 2026 | GIFT | |
| 🔒 Fresh data, subscribers only Nov 13, 2026 | EXERCISE | |
Booth Andrew Chief Financial Officer Nov 13, 2026 | BUY | $97.4K |
Thermopylae Holdings Ltd. 10%+ Owner Nov 13, 2026 | GIFT | 125,000 sh |
Thermopylae Holdings Ltd. 10%+ Owner Nov 12, 2026 | BUY | $698.9K |
Hayden Michael R Director Aug 24, 2026 | BUY | $570.4K |
Montalbano John S. Director Aug 18, 2026 | BUY | $110.3K |
Booth Andrew Chief Financial Officer Aug 14, 2026 | BUY | $383.9K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 8 bullish · 2 bearish · 1 mixed · 5 neutral- NEUTRAL SC 13G/ANov 13, 2026
CEO Carl Hansen filed an amended Schedule 13G/A disclosing a 19.7% beneficial ownership stake in…
CEO's stake is unchanged and passive; no signal of insider conviction change. Monitor next 10-Q for any insider trading activity or stake adjustments.
- BULLISH CLUSTERNov 13, 2026
Two insiders at AbCellera, including the CFO and a 10% owner, made open-market purchases totaling…
Monitor for additional insider buying or a Form 4 filing by other executives. The cluster follows positive earnings and clinical data, which may signal management's confidence in the pipeline and…
- BULLISH CLUSTERNov 13, 2026
Two insiders at AbCellera, including the CFO and a 10% owner, made open-market purchases totaling…
The CFO's first open-market purchase since joining and the 10% owner's material buy suggest insiders see value after the post-offering stock price. Monitor next quarter's revenue trajectory and…
- NEUTRAL 8-KNov 9, 2026
AbCellera reported Q3 2026 revenue of $10.6M (up 19% YoY from $9.0M) and a net loss of $40.8M…
Watch for ABCL635 late-stage development initiation in 2027 and 12-week/OLE data in early 2027; the Phase 2 efficacy data appear superior to approved NK3R antagonists, but the company remains…
All ABCL filing & press-release reports (16)
- SC 13G/A reportNov 13, 2026
- CLUSTER reportNov 13, 2026
- CLUSTER reportNov 13, 2026
- 8-K reportNov 9, 2026
- CLUSTER reportAug 24, 2026
- CLUSTER reportAug 18, 2026
- INST-CLUSTER reportAug 15, 2026
- 424B5 reportAug 11, 2026
- 8-K reportAug 10, 2026
- 8-K reportJul 29, 2026
- 3 reportJul 6, 2026
- 8-K reportJul 6, 2026
- 8-K reportJun 5, 2026
- 8-K reportMay 11, 2026
- CLUSTER reportFeb 27, 2026
- 8-K reportFeb 24, 2026